| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | CFO & Secretary
2 companies
Manu Ohri is CFO & Secretary at GTBP, with reported holdings spanning 2 companies. Manu Ohri's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.7M at current prices.
Manu Ohri's largest disclosed position is in GTBP as CFO & Secretary, worth about $1.6M. Net of sales, the GTBP filings show accumulation of 50,000 shares.
Manu Ohri has 7 Form 4 filings on record from July 2022 to January 2026, across 2 companies: Director at AXIL Brands (AXIL), 2024–2026; CFO & Secretary at GT Biopharma (GTBP), 2022–2023.
The 12 reported transactions were 5 stock awards, 4 other transactions, 2 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $25K and no sales.
The only open-market purchase was 50,000 shares of GTBP at an average $0.50 on April 6, 2023, about $25K. Twelve months later GTBP was down 70%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6, 2023 | GTBP Gt Biopharma, Inc. | CFO & Secretary | Buy | 50,000 | $0.50 | $25,000.00 | New | -32.2% | -69.9% |